Rodman & Renshaw initiated coverage on shares of Applied Genetic Technologies Corp (NDAQ:AGTC) in a report issued on Wednesday morning. The firm issued a buy rating and a $16.00 target price on the stock.

Applied Genetic Technologies Corp (NDAQ:AGTC) opened at 7.20 on Wednesday. The company has a market cap of $130.20 million and a price-to-earnings ratio of 12.52. The firm’s 50-day moving average is $7.49 and its 200 day moving average is $8.89. Applied Genetic Technologies Corp has a 12-month low of $6.07 and a 12-month high of $19.86.

Your IP Address:

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at

Applied Genetic Technologies Corp Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Receive News & Ratings for Applied Genetic Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corp and related companies with's FREE daily email newsletter.